Receive our newsletter – data, insights and analysis delivered to you
  1. Digital Disruption
  2. AI
September 4, 2020

Opyl develops AI software to predict outcomes of Covid-19 trials

Australian company Opyl has developed new software that can forecast the outcomes of Covid-19 clinical trials using artificial intelligence (AI).

Australian company Opyl has developed new software that can forecast the outcomes of Covid-19 clinical trials using artificial intelligence (AI).

The trial predictor technology identifies the drugs, vaccines, diagnostics or medical devices that are most likely to succeed and improve clinical trials.

In order to illustrate a ‘proof-of concept’, the company has applied the software to the existing vaccines and therapies targeting the virus in a major proof-of-concept study.

The study has found that therapies show a much higher probability of success in clinical studies.

Opyl has so far identified the two vaccines most likely to succeed their current stage of development (Phase) compared to all others.

The study also found that antibody therapies can get a positive Phase III outcome over all other programmes.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Opyl CEO Michelle Gallaher said: “We can see significant value in using the tool to inform clinical and treatment strategies, early procurement decision making and investments.”

“The early outcome of this software trial, investigating the 475 registered Covid-19 clinical trials related to vaccines or treatments, has delivered results that give us an indication of the power of the predictive platform in identifying the Covid-19 trials, or any drug or device trial, with the greatest chance of success.”

The Opyl software platform can work with drug and device development companies to refine their clinical trial approaches for improving outcomes of their clinical studies.

The AI platform makes use of existing and historical global data and considers all aspects related to the Covid-19 clinical trial.

As part of the platform’s next phase of development, the company will increase the data pool from additional clinical data sources and expand the variables to further train the algorithm.

Gallaher further added: “Although looking at the current pipeline of Covid-19 programmes is an initial application of the AI platform, we are not limiting ourselves to just Covid-19 trials.”

Opyl is currently discussing with companies and partners on other applications of the technology.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU